Stockreport

Galera Announces Results From Phase 1 Stage Of GRECO-1 Trial Of Rucosopasem With SBRT For NSCLC [TheStreet.com]

Galera Therapeutics, Inc.  (GRTX) 
PDF Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the randomized, double-blin [Read more]